Case report shows sustained remission in oligometastatic pancreatic cancer despite elevated CA19-9, suggesting new treatment insights.
INTRODUCTION: Persistent elevation of carbohydrate antigen 19-9 (CA19-9) during chemotherapy for pancreatic ductal adenocarcinoma (PDAC) is generally regarded as a marker of poor prognosis and systemic disease, often discouraging aggressive local treatment. However, the clinical significance of elevated CA19-9 levels in patients with oligometastatic recurrence remains controversial.
No takes yet. Share an insight, caveat, or question.
Takahashi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: